Form 4: Mereo BioPharma CFO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christine Fox, CFO of Mereo BioPharma Group plc, sold American Depositary Shares (ADS) to cover tax withholding obligations related to vested performance-based restricted stock units.
Summary
- Christine Fox, the Chief Financial Officer of Mereo BioPharma Group plc, filed a Form 4 detailing changes in beneficial ownership.
- On June 25, 2024, she sold 12,990 American Depositary Shares (ADS) at an average price of $3.6939 to cover tax obligations related to the vesting of performance-based restricted stock units.
- These sales were mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.
- On June 26, 2024, she sold 29,439 ADSs at an average price of $3.3932 for the same purpose.
- Following these transactions, Ms. Fox directly owns 57,571 ADSs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions are related to tax obligations and not discretionary trading.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. These filings are closely monitored by investors to gauge management's sentiment and potential future actions.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Performance-based restricted stock units vested. |
| 06/25/2024 | Sale of 12,990 ADSs at an average price of $3.6939. |
| 06/26/2024 | Sale of 29,439 ADSs at an average price of $3.3932. |
| 06/27/2024 | Date of signature on the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.